Archived Science Blog page from 2018. It stays on Science Blog so the original link still works. It is not a current article. Back to Science Blog

Herpes Vaccine – The Search for a Safe and Effective HSV-2 Vaccine

To those who have followed my blog in the past, please accept my apology for about 7 months of radio silence. I took a Sabbatical Leave at the Rocky Mountain Laboratories (http://www.niaid.nih.gov/about/organization/dir/rml/Pages/default.aspx) from Dec 2013 to June 2014 to brush up on my techniques, and develop some new assays to measure the T-cell response to a live-attenuated HSV-2 vaccine. Dr. Kim Hasenkrug and the great people in his lab made this a fabulous 7 months (http://www.niaid.nih.gov/LabsAndResources/labs/aboutlabs/lpvd/retroviralImmunologySection/Pages/hasenkrug.aspx). I learned a ton, and this was time well spent. I am a skier, and I can also report that Lost Trail ski area (http://www.losttrail.com/), which is 45 miles south of the lab, gets very high marks for tons of fresh powder in early 2014!

The last 2 months of my Sabbatical were ridiculously busy, and the 6 months since I returned to my home institution at SIU School of Medicine have been equally nuts. Very productive, but no time for a life and no time for the blog….hence the long silence.

So, without any more excuses, time to get down to business. I said in May 2014 that I would write three posts to address a reader’s questions, which went something like this: “Let’s discuss the therapeutic effect of a future vaccine. So basically the patient gets a vaccine shot in his arm, just like all other vaccines are given…How would an arm shot benefit the genital area for protective or therapeutic purpose?”

1) How does the human immune system respond to a HSV-2 vaccine?

2) Would a shot of HSV-2 vaccine in the arm be enough or would a shot in the behind provide better protection against genital herpes?

3) What is the goal of a ‘preventative’ versus a ‘therapeutic’ HSV-2 vaccine, and are each of these goals equally feasible?”

http://herpesvaccine.scienceblog.com/2014/05/10/how-does-the-human-immune-

http://herpesvaccine.scienceblog.com/2014/05/16/where-to-vaccinate-arm-or-the-bum/

I address the third and final question below in this blog post. Way to be a slacker Halford…..it only took you 7 months!! Well, better late than never…here it goes.

The basic principles on which the natural world and biology operate are generally pretty straightforward. That said, human beings have an infinite capacity to screw things up and make something that should be simple seem far more complex than necessary. This is the situation with HSV-2 vaccines…..what should be a simple problem has become a quagmire of contradictory logic and bad ideas.

A preventative HSV-2 vaccine would be simple if we considered a live-attenuated HSV-2 virus as the means of vaccination. Worked for smallpox, measles, chickenpox, etc and would work for HSV-2, but we have not tested any live HSV-2 vaccines in the U.S. So where things have gotten complicated is that scientists hypothesized that a live-attenuated HSV-2 vaccine might be “too dangerous” to pursue (based on no compelling evidence to support the claim), and scientists started developing “safer alternatives.” The need for these “safer alternatives” has never been proven, but nonetheless HSV-2 vaccine researchers have spent >99% of their time and money studying vaccine approaches based on just a few bits or pieces (subunits) of HSV-2.

When I say subunit vaccines, I am specifically talking about approaches like…….(1) the Agenus HerpV vaccine, (2) the Genocea GEN-003 vaccine (i.e., Herpevac + ½ of another HSV-2 protein), (3) Vical’s HSV-2 vaccine, (4) the Corridon / Admedus HSV-2 vaccine fundraising effort. This general subunit vaccine concept has been failing in human clinical trials since the mid-1980s, and there is no compelling evidence that the newer versions of this old concept will be any better as preventative HSV-2 vaccines.

If one INCLUDES a live-attenuated HSV-2 vaccine as an option in our human clinical testing of HSV-2 vaccine candidates, then a preventative HSV-2 vaccine should be a no-brainer provided that the live HSV-2 vaccine in question elicits (1) at least 30% of the pan-HSV-2 IgG antibody response that is observed in asymptomatic carriers of wild-type HSV-2 and (2) that this vaccine-induced HSV-2 antibody response is durable and is maintained at a detectable level for at least 3 years post-vaccination.

In contrast, if one EXCLUDES a live-attenuated HSV-2 vaccine as an option for human clinical testing of HSV-2 vaccine candidates (which has been the case in the U.S. for the past 30 years), well that would make it damned near impossible to develop an effective HSV-2 vaccine.

So, a preventative HSV-2 vaccine is easy if one uses the right tool that nature has provided us for the job (a live-attenuated vaccine), but human beings have complicated the issue by creating a scientific culture is which most ‘experts’ have arrived at precisely the wrong conclusion that “We should test any and all HSV-2 vaccine concepts except for the ‘most dangerous approach’ of a live-attenuated HSV-2 vaccine.”

Call me crazy, but I am going to go out on a limb and suggest that human testing of a well-vetted live-attenuated HSV-2 vaccine in n=20 people is probably much safer than what we have been doing for the past 30 years……watching n=10 to 20 million people per year get newly infected with HSV-2 while scientists keep tinkering with HSV-2 subunit vaccines that don’t work.

Everything I write above may be distilled into one sentence: The likelihood that a live-attenuated HSV-2 virus would function as a very effective, preventative vaccine to prevent HSV-2 genital herpes is similar to the probability that the sun will rise tomorrow.

I will be the first to admit that I don’t have a crystal ball, and I really cannot see into the future. However, in both cases, experience tells me that it would be prudent to assume these two things are very, very, very likely to come to pass, and thus we should probably plan accordingly. I have no plans to hang myself or shoot myself tonight on the off-chance that the sun won’t rise tomorrow, and the world will suddenly become an uninhabitable rock. Likewise, there is no basis in logic or reason to assume that a live-attenuated HSV-2 vaccine should be any less likely to succeed than the live-attenuated viruses that have been successfully used to control smallpox, yellow fever, polio, mumps, measles, rubella, and chickenpox.

As certain as I am that a PREVENTATIVE HSV-2 VACCINE is infinitely feasible, I would put myself somewhere precisely in the middle when it comes to the feasibility of a THERAPEUTIC HSV-2 VACCINE.

Before proceeding, I offer my simple take-home message on therapeutic HSV-2 vaccines in the next two paragraphs.

The promise of a therapeutic HSV-2 vaccine lies in that, in theory, it might be (1) administered to a person with uncontrolled HSV-2 genital herpes outbreaks and (2) might re-program that person’s adaptive immune system to do a better job in the future of controlling their HSV-2 infection such that their outbreaks either stopped altogether, or occurred at a much lower frequency. The importance of this possibility for tens of millions of herpes sufferers cannot be overstated, and thus the possibility of a therapeutic HSV-2 vaccine deserves the scientific community’s full attention.

Despite the importance of this possibility, it is equally important for HSV-2 genital herpes sufferers to recognize that,

, there is simply no historical precedent that dictates that a therapeutic HSV-2 vaccine MUST be possible. A HSV-2 therapeutic vaccine is an important possibility, but it remains to be determined if the idea falls into the realm of “science” or “science fiction.” Maybe someone who has lived with symptoms of recurrent HSV-2 genital herpes that have been ongoing for years may be “dialed back” to zero symptoms, or close to zero symptoms, by immunizing them with a series of “therapeutic HSV-2 vaccine shots.” It is an appealing idea (or hypothesis), but it is a hypothesis that remains largely untested, and thus unknown.

Below I consider some of the theory that underlies (1) the counterargument why a therapeutic HSV-2 vaccine SHOULD NOT be possible and (2) the argument why a therapeutic HSV-2 vaccine MAY BE possible.

The against therapeutic HSV-2 vaccines that immunologists (including myself) have been trained to think in terms of is that…….”immunity to HSV-2″ is a binary variable (i.e., a 0 or a 1)……you either have it or you do not.

With this rationale in mind, the story goes something like this………….

After a person is infected with HSV-2, their body’s B- and T-lymphocytes mount a response to the HSV-2 virus. The activated B-lymphocytes produce HSV-2-specific antibodies that circulate through the blood and lymph. The activated T-lymphocytes enter the circulation and migrate into HSV-2-infected tissues. Collectively, the development of (1) HSV-2-specific antibodies and (2) HSV-2-specific T-cells constitutes “immunity to HSV-2,” and under this logic, a therapeutic HSV-2 vaccine should NOT be possible.

That is, if being infected with wild-type HSV-2 is sufficient, in and of itself, for a person to convert from being “naïve” (i.e., a 0) to “HSV-2-immune” (i.e., a 1), then how could a therapeutic HSV-2 vaccine possibly help? Is the therapeutic HSV-2 vaccine going to make them a 1+?

First, in the natural world, complex biological processes like the development of an adaptive immune response to HSV-2 are rarely (if ever) describable in terms of a purely binary variable (i.e., black=0 or white=1). Hence, a more realistic (although still overly simplistic) way to think of “protective immunity to HSV-2” is to think of this immunity as lying on a scale of 0.0% to 100.0% possible protection against HSV-2.

Second, if we consider the actual basis of immunity to HSV-2, this relies on a diverse population of millions of B-lymphocytes, CD4 T-helper lymphocytes, CD8-lymphocytes, and likely some less studied CD4+CD25+ regulatory T-lymphocytes (which can dampen a protective immune response, and push the immune system towards “tolerance”). Aside from the sheer numbers of cells involved, these lymphocytes may recognize hundreds to thousands of different bits (epitopes) of HSV-2 distributed across 75 viral proteins. To help put this in perspective, it is useful to remember that a single B-cell or T-cell recognizes a very small piece of HSV-2 on the order of 6 to 25 amino-acids in length. In total, HSV-2 encodes 39,100 amino acids worth of protein. Given the reality of how the biological system operates, it is really not accurate to suggest that “immunity to HSV-2” may be described as a binary variable, and thus to think of human beings as either being HSV-2 seronegative (naïve) or HSV-2 seropositive (immune). Such descriptions are such gross oversimplifications of the truth that they are about 10% right and are about 90% wrong. Nonetheless, that is how most doctors and scientists have been trained to think of immunity to HSV-2 (+/-). This mindset (1) creates the illusion of understanding for doctors; (2) is based on ignorance of how the adaptive immune response to HSV-2 actually operates; and (3) creates no opportunity for people to rationally discuss and consider the possibility of a therapeutic HSV-2 vaccine, which requires a more accurate and nuanced understanding of HSV-2 immunity.